Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Recent advances in pulmonary fibrosis: implications for scleroderma.

Homer RJ, Herzog EL.

Curr Opin Rheumatol. 2010 Nov;22(6):683-9. doi: 10.1097/BOR.0b013e32833ddcc9. Review.

PMID:
20693906
2.

Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease.

Veraldi KL, Hsu E, Feghali-Bostwick CA.

Curr Rheumatol Rep. 2010 Feb;12(1):19-25. doi: 10.1007/s11926-009-0071-8. Review.

PMID:
20425529
3.

Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance.

Cepeda EJ, Reveille JD.

Curr Opin Rheumatol. 2004 Nov;16(6):723-32. Review.

PMID:
15577611
4.

Nailfold capillaroscopic findings in systemic sclerosis related lung fibrosis and in idiopathic lung fibrosis.

Corrado A, Carpagnano GE, Gaudio A, Foschino-Barbaro MP, Cantatore FP.

Joint Bone Spine. 2010 Dec;77(6):570-4. doi: 10.1016/j.jbspin.2010.02.019. Epub 2010 May 23.

PMID:
20547086
5.

Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis.

Owens GR, Paradis IL, Gryzan S, Medsger TA Jr, Follansbee WP, Klein HA, Dauber JH.

J Lab Clin Med. 1986 Mar;107(3):253-60.

PMID:
3950467
6.

The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.

Thachil J.

Med Hypotheses. 2009 Mar;72(3):291-3. doi: 10.1016/j.mehy.2008.09.045. Epub 2008 Nov 25.

PMID:
19036527
7.

Angiotensin II type 1 and 2 receptors and lymphatic vessels modulate lung remodeling and fibrosis in systemic sclerosis and idiopathic pulmonary fibrosis.

Parra ER, Ruppert AD, Capelozzi VL.

Clinics (Sao Paulo). 2014 Jan;69(1):47-54. doi: 10.6061/clinics/2014(01)07.

8.

Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model.

Wuyts WA, Willems S, Vos R, Vanaudenaerde BM, De Vleeschauwer SI, Rinaldi M, Vanhooren HM, Geudens N, Verleden SE, Demedts MG, Thomeer M, Verbeken EK, Verleden GM.

Exp Lung Res. 2010 Dec;36(10):602-14. doi: 10.3109/01902148.2010.492895. Epub 2010 Sep 27.

PMID:
20874225
9.
10.

Interstitial lung disease in scleroderma.

White B.

Rheum Dis Clin North Am. 2003 May;29(2):371-90. Review.

PMID:
12841300
11.
12.
13.

T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis.

Chizzolini C.

Curr Opin Rheumatol. 2008 Nov;20(6):707-12. doi: 10.1097/BOR.0b013e32830c45ae. Review.

PMID:
18946333
14.

Current and future direction in the management of scleroderma.

Brady SM, Shapiro L, Mousa SA.

Arch Dermatol Res. 2016 Sep;308(7):461-71. doi: 10.1007/s00403-016-1647-6. Epub 2016 Apr 30. Review.

PMID:
27139430
15.

Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.

Schachna L, Medsger TA Jr, Dauber JH, Wigley FM, Braunstein NA, White B, Steen VD, Conte JV, Yang SC, McCurry KR, Borja MC, Plaskon DE, Orens JB, Gelber AC.

Arthritis Rheum. 2006 Dec;54(12):3954-61.

16.
17.

Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?

Murray LA, Rubinowitz A, Herzog EL.

Curr Opin Rheumatol. 2012 Nov;24(6):656-62. Review.

PMID:
22955020
18.

[Physiopathology of scleroderma].

Fleischmajer R, Perlish JS, Maquart FX, Kalis B.

Ann Dermatol Venereol. 1993;120(2):157-66. Review. French.

PMID:
8363310
19.

Animal models of scleroderma: lessons from transgenic and knockout mice.

Derrett-Smith EC, Denton CP, Sonnylal S.

Curr Opin Rheumatol. 2009 Nov;21(6):630-5. doi: 10.1097/BOR.0b013e32833130c1. Review.

PMID:
19730378
20.

[The mechanism of lung tissue remodeling in the progression of idiopathic pulmonary fibrosis].

Kogan EA, Tyong FV, Demura SA.

Arkh Patol. 2010 Jul-Aug;72(4):30-6. Russian.

PMID:
21086635

Supplemental Content

Support Center